A kit formulation for the preparation of immunoliposome drug in combined chemotherapy and radionuclide therapy is disclosed, which consists: (1) a vial A containing proteins; (2) a vial B containing Traut's reagent; (3) a vial C containing DSPC, Cholesterol, mPEG-DSPE, Mal-DSPE-PEG and chemotherapy drug; (4) a vial D containing BMEDA, gluconate acetate, SnCl2; (5) a vial E which containing radionuclide solution. The procedure using the kit comprises: (i) withdraw the radionuclide solution from the vial E; (ii) inject the solution into the vial D for enabling reaction; (iii) withdraw the contents of the vial B and inject into the vial A; (iv) withdraw the contents of the protein and Traut's reagent mixtures from the vial A and inject into the vial C for enabling reaction; (v) withdraw the contents of the immunoliposome from the vial C; (vi) inject the immunoliposome into the vial D of step (ii) for enabling reaction.